title: Alpha-thalassaemia prenatal diagnosis by two PCR-based methods.
abstract: In Cyprus all couples carrying alpha0-thalassaemia mutations are detected in the course of the thalassaemia carrier screening program and prenatal diagnosis is offered to all of them. Prenatal diagnosis for alpha-thalassaemia is routinely done by two independent molecular methods. With the first method, the mutations of the parents are directly determined by gap-PCR and then the chorionic villus sample (CVS) is examined for the presence of these mutations. With the other method, a (CA)n repeat polymorphic site located between the psialpha1- and alpha2-globin genes is used for determining the presence or absence of the normal and mutant alleles. In the period from 1995 to 1999, molecular analysis of 46 couples in which haematological data were consistent with deletion of two alpha-globin genes in both partners indicated that only 13 of them were actually at risk for haemoglobin (Hb) Bart's hydrops fetalis and prenatal diagnosis was provided in 16 pregnancies. The molecular diagnosis was possible in all cases with the use of both gap-PCR and (CA)n repeat polymorphisms analysis. No misdiagnosed cases for alpha-thalassaemia have been reported to date.
authors.affiliation: The Cyprus Institute of Neurology and Genetics, PO Box 23462, Nicosia 1463, Cyprus. marinakl@mdrtc.cing.ac.cy
authors.forename: M
authors.initials: M
authors.lastname: Kleanthous
authors.forename: K
authors.initials: K
authors.lastname: Kyriacou
authors.forename: A
authors.initials: A
authors.lastname: Kyrri
authors.forename: E
authors.initials: E
authors.lastname: Kalogerou
authors.forename: P
authors.initials: P
authors.lastname: Vassiliades
authors.forename: A
authors.initials: A
authors.lastname: Drousiotou
authors.forename: I
authors.initials: I
authors.lastname: Kallikas
authors.forename: P
authors.initials: P
authors.lastname: Ioannou
authors.forename: M
authors.initials: M
authors.lastname: Angastiniotis
mesh_terms: D000328:Adult; D015193:Chorionic Villi Sampling; D003535:Cyprus / Q000453:epidemiology; D004247:DNA / Q000032:analysis; D004252:DNA Mutational Analysis; D017931:DNA Primers / Q000737:chemistry; D005260:Female; D017353:Gene Deletion; D005820:Genetic Testing / Q000379:methods*; D005914:Globins / Q000032:analysis / Q000235:genetics; D006455:Hemoglobins, Abnormal / Q000032:analysis / Q000235:genetics; D006801:Humans; D015160:Hydrops Fetalis / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics; D008297:Male; D017720:Molecular Epidemiology; D016133:Polymerase Chain Reaction / Q000379:methods*; D011110:Polymorphism, Genetic; D011247:Pregnancy; D012091:Repetitive Sequences, Nucleic Acid; D012680:Sensitivity and Specificity; D017085:alpha-Thalassemia / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics
chemical_list: D017931:DNA Primers; D006455:Hemoglobins, Abnormal; D005914:Globins; D004247:DNA; C030448:hemoglobin Bart's